Segall Bryant & Hamill LLC Acquires 5,447 Shares of Gilead Sciences, Inc. (GILD)

Segall Bryant & Hamill LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 39.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,174 shares of the biopharmaceutical company’s stock after buying an additional 5,447 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Gilead Sciences were worth $1,358,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Global X Management Co. LLC raised its stake in shares of Gilead Sciences by 10.0% in the 1st quarter. Global X Management Co. LLC now owns 17,200 shares of the biopharmaceutical company’s stock worth $1,297,000 after buying an additional 1,562 shares in the last quarter. Diamond Hill Capital Management Inc. raised its stake in shares of Gilead Sciences by 1,970.1% in the 1st quarter. Diamond Hill Capital Management Inc. now owns 1,054,552 shares of the biopharmaceutical company’s stock worth $79,503,000 after buying an additional 1,003,610 shares in the last quarter. FDx Advisors Inc. raised its stake in shares of Gilead Sciences by 3.2% in the 1st quarter. FDx Advisors Inc. now owns 46,775 shares of the biopharmaceutical company’s stock worth $3,526,000 after buying an additional 1,469 shares in the last quarter. Albert D Mason Inc. bought a new stake in shares of Gilead Sciences in the 1st quarter worth $424,000. Finally, Hennessy Advisors Inc. raised its stake in shares of Gilead Sciences by 129.4% in the 1st quarter. Hennessy Advisors Inc. now owns 69,500 shares of the biopharmaceutical company’s stock worth $5,240,000 after buying an additional 39,200 shares in the last quarter. Institutional investors own 78.01% of the company’s stock.

A number of analysts have recently commented on the company. BidaskClub downgraded Gilead Sciences from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 20th. ValuEngine downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, June 27th. Barclays dropped their price objective on Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, May 2nd. Leerink Swann set a $72.00 price objective on Gilead Sciences and gave the stock a “market perform” rating in a research note on Wednesday, May 2nd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 2nd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $88.00.

In related news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $77.85, for a total transaction of $3,892,500.00. Following the transaction, the director now directly owns 3,067,762 shares of the company’s stock, valued at $238,825,271.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 150,000 shares of company stock worth $10,839,500 over the last three months. 1.16% of the stock is owned by insiders.

Shares of Gilead Sciences stock opened at $73.59 on Monday. The firm has a market cap of $95.40 billion, a PE ratio of 8.60, a P/E/G ratio of -5.61 and a beta of 1.03. The company has a current ratio of 3.00, a quick ratio of 2.92 and a debt-to-equity ratio of 1.23. Gilead Sciences, Inc. has a 12-month low of $64.27 and a 12-month high of $89.54.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.56 by $0.35. The company had revenue of $5.65 billion for the quarter, compared to analyst estimates of $5.20 billion. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. Gilead Sciences’s revenue for the quarter was down 20.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.56 earnings per share. equities research analysts predict that Gilead Sciences, Inc. will post 6.56 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 27th. Stockholders of record on Friday, September 14th will be given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date is Thursday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Recommended Story: Should I invest in “strong buy” stocks?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply